Ameriprise Financial Inc Oramed Pharmaceuticals Inc. Transaction History

Ameriprise Financial Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.6 - $9.91 $92,000 - $198,200	20,000 Added 102.43%	39,525 $256,000
Q2 2022 Aug 15, 2022	SELL	$3.72 - $9.0 $48,267 - $116,775	-12,975 Reduced 39.92%	19,525 $89,000
Q1 2022 May 16, 2022	BUY	$8.19 - $13.89 $26,740 - $45,350	3,265 Added 11.17%	32,500 $281,000
Q4 2021 Feb 14, 2022	SELL	$12.98 - $29.75 $56,138 - $128,668	-4,325 Reduced 12.89%	29,235 $417,000
Q3 2021 Nov 15, 2021	BUY	$12.13 - $23.82 $407,082 - $799,399	33,560 New	33,560 $738,000
Q2 2021 Aug 16, 2021	SELL	$8.34 - $14.59 $99,846 - $174,671	-11,972 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.22 - $11.33 $50,521 - $135,642	11,972 New	11,972 $122,000

6.37M

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $91.2M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.